Clinical significance of provoked coronary spasm at chronic stage in patients who underwent successful complete coronary revascularization with first-generation drug-eluting stents


Background: Provoked spasm might have influence on cardiovascular events even after successful DES implantation. Methods and results: A consecutive 122 patients who underwent first-generation DES (CypherTM, and TaxusTM) implantation and had no residual stenosis at follow-up coronary angiography were included. All patients also underwent acetylcholine provocation test (ACh) at follow-up angiography. Age, sex, coronary risk factors (smoking, hypertension, diabetes mellitus, dyslipidemia), medication (calcium channel blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, nitrates, β blockers, statins), duration from stent implantation to follow-up angiography (15.5 ± 14.5 months), old myocardial infarction, Ach + were included as variables for multivariate analysis for cardiovascular events (angina pectoris without intervention, target lesion revascularization, acute myocardial infarction, definite or probable stent thrombosis, cardiac death, and stroke). ACh provocation test was positive in 64.8%. The following events occurred during a mean follow-up period of 26.9 ± 9.5 months; angina pectoris without intervention in 12, very late stent thrombosis in 1, acute myocardial infarction in 1, sudden death in 1, and stroke in 4. By Adjusted Cox hazard model, age was the independent predictor of future cardiovascular events. ACh was unbalanced data for Cox hazard model, and by logistic regression model, ACh was the strongest predictor. Conclusions: Coronary endothelial dysfunction at chronic stage is the strongest predictor of further prognosis in patients with first-generation DES.

Share and Cite:

Ito, S. , Nakasuka, K. , Sekimoto, S. , Miyata, K. , Inomata, M. , Yoshida, T. , Tamai, N. , Saeki, T. , Suzuki, S. , Murakami, Y. , Morino, A. , Shimizu, Y. and Sato, K. (2013) Clinical significance of provoked coronary spasm at chronic stage in patients who underwent successful complete coronary revascularization with first-generation drug-eluting stents. World Journal of Cardiovascular Diseases, 3, 25-32. doi: 10.4236/wjcd.2013.34A005.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Azar, R.R. (2010) Diffuse coronary spasm in a patient with a recent stent. JACC: Cardiovascular Interventions, 3, 459-460. doi:10.1016/j.jcin.2009.11.023
[2] Fuke, S., Maekawa, K., Kawamoto, K., Saito, H., Sato, T., Hioka, T. and Ohe, T. (2007) Impaired endothelial vasomotor function after sirolimus-eluting stent implantaion. Circulation Journal, 71, 220-225. doi:10.1253/circj.71.220
[3] Hamilos, M., Sarma, J., Ostojic, M., Cuisset, T., Sarno, G., Melikian, N., Ntalianis, A., Muller, O., et al. (2008) Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: Evidence for device-specific responses. Circulation: Cardiovascular Interventions, 1, 193-200. doi:10.1161/CIRCINTERVENTIONS.108.797928
[4] Hofma, S.H., Van Der Giessen, W.J., Van Dalen, B.M., Lemos, P.A., McFadden, E.P., Sianos, G., Lighhart, J.M. R., Van Essen, D., et al. (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European Heart Journal, 27, 166-170. doi:10.1093/eurheartj/ehi571
[5] Ito, S., Nakasuka, K., Morimoto, K., Inomata, M., Yoshida, T., Tamai, N., Suzuki, S., Murakami, Y., et al. (2011) Angiographic and clinical characteristics of patients with acetylcholine-induced coronary vasospasm on follow-up coronary angiography following drug-eluting stent implantation. Journal of Invasive Cardiology, 23, 57-64.
[6] Jabs, A., Gobel, S., Wenzel, P., Kleschyov, A.L., Hortmann, M., Oelze, M., Daiber, A. and Munzel, T. (2008) Sirolimus-induced vasomotor dysfunction Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. Journal of the American College of Cardiology, 51, 2130-2138. doi:10.1016/j.jacc.2008.01.058
[7] Kim, J.W., Suh, S.Y., Choi, C.U., Na, J.O., Kim, E.J., Rha, S.W., Park, C.G., Seo, H.S., et al. (2008) Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. JACC: Cardiovascular Interventions, 1, 65-71. doi:10.1016/j.jcin.2007.11.002
[8] Muhlenstein, J.B. (2008) Endothelial dysfunction associated with drug-eluting stents. Journal of the American College of Cardiology, 51, 39-40.
[9] Shin, D.I., Kim, P.J., Seung, K.-B., Kim, D.B., Kim, M.-J., Chang, K., Lim, S.M., Jeon, D.S., et al. (2007) Drug-eluting stent implantation could be asscoiated with long-term coronary endothelial dysfunction comparison between sirolimus-eluting stent and paclitaxel-eluting stent. International Heart Journal, 48, 553-567. doi:10.1536/ihj.48.553
[10] Shiroto, T., Yasuda, S., Tsuburaya, R., Ito, Y., Takahashi, J., Ito, K., Ishibashi-Ueda, H., Shimokawa, H. (2009) Role of Rho-Kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in pigs in vivo. Journal of the American College of Cardiology, 54, 2321-2329. doi:10.1016/j.jacc.2009.07.045
[11] Togni, M., Raber, L., Cocchia, R., Wenaweser, P., Cook, S., Windecker, S., Meier, B., Hess, O.M. (2007) Local vascular dysfunction after coronary paclitaxel-eluting stent implantaion. International Journal of Cardiology, 120, 212-220. doi:10.1016/j.ijcard.2006.09.021
[12] Togni, M., Windecker, S., Cocchia, R., Wenaweser, P., Cook, S., Billinger, M., Meier, B. and Hess, O.M. (2005) Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. Journal of the American College of Cardiology, 46, 231-236. doi:10.1016/j.jacc.2005.01.062
[13] Maekawa, K., Kawamoto, K., Fuke, S., Yoshioka, R., Saito, H., Sato, T. and Hioka, T. (2006) Severe endothelial dysfunction after sirolimud-eluting stent implantation. Circulation, 113, e850-e-851. doi:10.1161/CIRCULATIONAHA.105.597948
[14] Hofma, S.H., Brouwer, J., Velders, M.A., Van’t Hof, A.W., Smits, P.C., Quere, M., de Vries, C.J. and Van Boven, A.J. (2012) Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: 1-year results of the randomized XAMI (xiencev stent vs. cypher stent in primary PCI for acute myocardial infarction) trial. Journal of the American College of Cardiology, 60, 381387. doi:10.1016/j.jacc.2012.01.073
[15] Palmerini, T., Kirtane, A.J., Serruys, P.W., Smits, P.C., Kedhi, E., Kereiakes, D., Sangiorgi, D., Bacchi Reggiani, L., et al. (2012) Stent thrombosis with everolimus-eluting stents: Meta-analysis of comparative randomized controlled trials. Circulation: Cardiovascular Interventions, 5, 357-364. doi:10.1161/CIRCINTERVENTIONS.111.967083
[16] Bertrand, M.E., LaBlanche, J.M., Tilmant, P.Y., Thieuleux, F.A., Delforge, M.R., Carre, A.G., Asseman, P., Berzin, B., et al. (1982) Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation, 65, 1299-1306. doi:10.1161/01.CIR.65.7.1299
[17] Curry, R.C.J., Pepine, C.J., Sabom, M.B., Feldman, R.L., Christie, L.G. and Conti, C.R. (1977) Effects of ergonovine in patients with and without coronary artery disease. Circulation, 56, 803-809. doi:10.1161/01.CIR.56.5.803
[18] Okumura, K., Yasue, H., Matsuyama, K., Ogawa, H., Morikami, Y., Obata, K. and Sakaino, N. (1992) Effect of acetylcholine on the highly stenotic coronary artery: Difference between the constrictor response of the infarctrelated artery and that of the noninfarct-related artery. Journal of the American College of Cardiology, 19, 752-758. doi:10.1016/0735-1097(92)90513-M
[19] Tanabe, Y., Itoh, E., Suzuki, K., Ito, M., Hosaka, Y., Nakagawa, I. and Kumakura, M. (2002) Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. Journal of the American College of Cardiology, 39, 1120-1126. doi:10.1016/S0735-1097(02)01746-1
[20] Schachinger, V., Britten, M.B. and Zeiher, A. (2000) Impaired epicardial coronay vasoreactivity predicts for adverse cardiovascular events during long-term follow up. Circulation, 101, 1899-1906. doi:10.1161/01.CIR.101.16.1899
[21] Egashira, K., Kikuchi, Y., Sagara, T., Sugihara, M. and Nakamura, M. (1987) Long-term prognosis of vasospastic angina without significant atherosclerotic coronary artery disease. Japanese Heart Journal, 28, 841-849. doi:10.1536/ihj.28.841
[22] Nakamura, M., Takeshita, A. and Nose, Y. (1987) Clinical characteristics associated with myocardial infarction, arrhythmia, and sudden death in patients with vasospastic angina. Circulation, 75, 1110-1116. doi:10.1161/01.CIR.75.6.1110
[23] Beltrame, J.F., Sasayama, S. and Maseri, A. (1999) Racial heterogeneity in coronary artery vasomotor reactivity: Differences between Japanese and Caucasian patients. Journal of the American College of Cardiology, 33, 1442-1452. doi:10.1016/S0735-1097(99)00073-X
[24] Pristipino, C., Beltrame, J.F., Finocchiaro, M.L., Hattori, R., Fujita, M., Mongiardo, R., Cianflone, D., Sanna, T., et al. (2000) Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation, 101, 1102-1108. doi:10.1161/01.CIR.101.10.1102
[25] Katoh, D., Mizuno, Y., Harada, E., Ito, T., Morikawa, Y., Nakagawa, H., Saito, Y., Yoshimura, M., et al. (2012) High incidence of provoked coronary spasm in the presence of a stent after myocardial infarction: Therapeutic and prognostic implications. Coronary Artery Disease, 23, 141-145. doi:10.1097/MCA.0b013e32835115ee
[26] Sueda, S., Ochi, N., Kawada, H., Matsuda, S., Hayashi, Y., Tsuruoka, T. and Uraoka, T. (1999) Frequency of provoked coronary vasospasm in patients undergoing coronary angiography with spasm provocation test of acetylcholine. American Journal of Cardiology, 83, 1186-1190. doi:10.1016/S0002-9149(99)00057-0
[27] Yasue, H., Horio, Y., Nakamura, N., Fujii, H., Imoto, N., Sonoda, R., Kugiyama, K., Obata, K., et al. (1986) Induction of coronary artery spasm by acetylcholine in patients with variant angina: Possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation, 74, 955-963. doi:10.1161/01.CIR.74.5.955
[28] Cutlip, D.E., Windecker, S., Mehran, R., Boam, A., Cohen, D.J., Van Es, G.A., Steg, P.G., Morel, M.A., et al. (2007) Clinical end points in coronary stent trials: A case for standardized definitions. Circulation, 115, 2344-2351. doi:10.1161/CIRCULATIONAHA.106.685313
[29] Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., Katus, H.A., Apple, F.S., et al. (2012) Third universal definition of myocardial infarction. Journal of the American College of Cardiology, 60, 1581-1598. doi:10.1016/j.jacc.2012.08.001
[30] Minami, Y., Kaneda, H., Inoue, M., Ikutomi, M., Morita, T. and Nakajima, T. (2012) Endothelial dysfunction following drug-eluting stent implantation: A systematic review of the literature. International Journal of Cardiology, 165, 222-228.
[31] Kim, J.W., Seo, H.S., Park, J.H., Na, J.O., Choi, C.U., Lim, H.E., Kim, E.J., Rha, S.-W., et al. (2009) A prospective randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimusversus a sirolimus-eluting stent. Journal of the American College of Cardiology, 53, 1653-1659. doi:10.1016/j.jacc.2009.01.051
[32] Egashira, K., Araki, H., Takeshita, A. and Nakamura, M. (1989) Silent myocardial ischemia in patients with variant angina. Japanese Circulation Journal, 53, 1452-1457. doi:10.1253/jcj.53.1452
[33] Holmes, Jr., D.R., Kereiakes, D.J., Garg, S., Serruys, P.W., Dehmer, G.J., Ellis, S.G., Williams, D.O., Kimura, T., et al. (2010) Stent thrombosis. Journal of the American College of Cardiology, 56, 1357-1365. doi:10.1016/j.jacc.2010.07.016
[34] Hamasaki, S. and Tei, C. (2011) Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. Journal of Cardiology, 57, 231-238. doi:10.1016/j.jjcc.2011.02.003
[35] Shimokawa, H., Nagasawa, K., Irie, T., Egashira, S., Egashira, K., Sagara, T., Kikuchi, Y. and Nakamura, M. (1988) Clinical characteristics and long-term prognosis of patients with variant angina. A comparative study between western and Japanese populations. International Journal of Cardiology, 18, 331-349. doi:10.1016/0167-5273(88)90052-6
[36] Tsuburaya, R., Yasuda, S., Shiroto, T., Ito, Y., Gao, J.Y., Aizawa, K., Kikuchi, Y., Ito, K., et al. (2012) Long-term treatment with nifedipine suppresses coronary hyperconstricting responses and inflammatory changes induced by paclitaxel-eluting stent in pigs in vivo: possible involvement of Rho-kinase pathway. European Heart Journal, 33, 791-799. doi:10.1093/eurheartj/ehr145
[37] ENCORE Investigators (2003) Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE I study (Evaluation of nifedipine and cerivastatin on recovery of coronary endothelial function). Circulation, 107, 422-428. doi:10.1161/01.CIR.0000046488.52939.BF
[38] Luscher, T.F., Pieper, M., Tendera, M., Vrolix, M., Rutsch, W., Van Den Branden, F., Gil, R., Bischoff, K. O., et al. (2009) A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: The ENCORE II study. European Heart Journal, 30, 1590-1597. doi:10.1093/eurheartj/ehp151

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.